Novartis Pelacarsen Miss Hits Amgen as Lp(a) Class Faces New Test
The 8,323-patient Lp(a)HORIZON trial failed its cardiovascular primary; Amgen shares fell about 10% on class read-through. Business • Biotech •...
The 8,323-patient Lp(a)HORIZON trial failed its cardiovascular primary; Amgen shares fell about 10% on class read-through. Business • Biotech •...
Cash deal with Warburg Pincus and Berkshire Partners aims to lock in scarce aero castings; close targeted for the second...